Doubts About The Effectiveness Of Janssen Return, A Booster Dose Is Considered
Doubts about the efficacy of the Janssen vaccine against virus variants return. Thus, the experts from the Vaccine Conference, says Cadena Ser, propose to the Public Health commission that the possibility of administering a booster dose be assessed.
The beginning of Janssen’s doubts
The first doubts about the Janssen vaccine began to emerge with the advancement of the Delta variant of the coronavirus. Thus, several US experts began to recommend and inject second doses of Pfizer or Moderna.
“There is no question that people who get the J&J vaccine are less protected against the disease” than those who get two doses of the other injections, Stanford professor Dr. Michael Lin told Reuters. In the same vein, the agency notes, vaccine expert Peter Hotez, a doctor from Baylor College of Medicine, said in a tweet that adding a second dose of Janssen or one of the mRNA vaccines could provide broader protection, but we need CDC and FDA data and guidance. “
The pharmaceutical company that developed the vaccine solved this crisis by announcing that its drug was effective and highly neutralizing against Delta. “The recently announced studies strengthen the ability of Johnson & Johnson’s Covid-19 vaccine to help protect the health of people around the world,” said Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson. “We believe that our vaccine offers long-lasting protection against COVID-19 and causes neutralizing activity against the Delta variant,” he adds.
High percentage of vaccinated with Janssen in UC
A recent study carried out by the pharmacovigilance centers of Lyon and Grenoble, and published by the French National Agency for the Safety of Medicines, has once again sowed doubts. Specifically, it has reflected in its conclusions the presence in ICU of a high number of vaccinated with Janssen.
“A potential signal has been highlighted in the face of a large number of cases of failure of the vaccine with Janssen, with patients in intensive care or who have died from COVID-19, the majority with serious risk comorbidities,” concludes the article published this Tuesday.
